As the FDA approved Afinitor's new breast cancer indication last year, analysts estimated that it could add up to $1.5 billion to Afinitor's peak sales. That's a nice chunk of change to help Novartis make up for Diovan's patent-cliff losses. But the U.K.'s cost-effectiveness watchdogs have another idea.
Sanofi's cancer drug Zaltrap has again fallen into a price trap. The cost watchdog in the U.K. said it does not find the benefits of the colorectal cancer drug outweigh its high price.
Bristol-Myers Squibb and AstraZeneca persuaded the U.K.'s cost-effectiveness agency to make an about-face on their new diabetes drug Forxiga.
Regulators have again turned down Roche's cancer drug Avastin for payment by the National Health System (NHS), this time for use on a recurrent, advanced ovarian cancer. But that doesn't mean patients won't get it.
The U.K.'s cost-effectiveness watchdog has turned away Afinitor for breast cancer. The Novartis drug doesn't offer enough value for the money, the National Institute for Health and Clinical Excellence says.
The U.K.'s cost-effectiveness experts have changed their mind on Xolair--again. The National Institute for Health and Clinical Excellence threatened to pull its recommendation for the asthma drug last November.
U.K. cost-effectiveness watchdogs kicked Novartis' ($NVS) new cancer drug Jakavi to the curb, saying the myelofibrosis treatment isn't worth the £3,600-per-month ($5,999) price.
AstraZeneca's new chief executive, Pascal Soriot wants the diabetes marketing teams from the AstraZeneca and Bristol-Myers Squibb partnership to think deep thoughts about how they are going to sell more products. To do that, they have been put together and the team then sequestered in their own home away from the distractions of their respective companies.
Forxiga, approved in November for sale in the EU, failed to impress the gatekeepers at the National Institute for Health and Clinical Excellence. Essentially, NICE isn't yet convinced that Forxiga works any better as an add-on therapy than other drugs already in use.
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker's eye treatment, recommending the pricey injection for use in diabetics.